Discover how GreenLight Pharmaceuticals Ltd is aiming to advance clinical research, access and education regarding medical cannabis in Europe.

Established in 2014, GreenLight Pharmaceuticals Ltd is an Irish biopharmaceutical company focused on developing safe and effective plant-based medicines. GreenLight specialises in phytocannabinoid research and clinical development. The company is based in Dublin but has recently created a UK based subsidiary and has plans to expand its world of medical cannabis in Europe.

Tilray Inc. is expanding its European leadership team and setting up a hub in Portugal, deepening its planned international reach.

The company appointed five senior members to its European team, according to a statement Friday. Arne Wilkens, a former executive at the German pharmaceuticals company AiCuris, will take on the role of vice president of business expansion in Europe.

Solutions for harvesting and processing the entire hemp plant are in overwhelming demand as inventors, engineers and other assorted tinkerers work feverishly to develop ground-breaking technology and machines for both small and large hemp-centric operations.

That was the general conclusion of 30 industry leaders from 14 countries who gathered to discuss the global state of Hemp Machines & Technology at a micro-summit recently held at HempToday’s International Center of Excellence in Poland.

Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that it has entered into a letter agreement (the “Letter Agreement“) to become a strategic supplier of medical cannabis products to Canurius UG (“Canurius”), for the sale and distribution of cannabis products in Germany with the potential for expansion

Dr Franjo Grotenhermen, founder and Chairman of the ACM and IACM, provides a deeper insight into medical cannabis delivery systems in Germany, along with patient experience and more.

Read entire article here.

White smoke emanating from Germany’s medical agency signals the wait is over to find out which firms have been awarded medicinal cannabis tenders for Europe’s top market.

Two Canadian firms, Aphria, and Aurora Cannabis and Germany’s Demecan have won out, it has emerged.

The three companies will split a four-year tender to grow 10,400kg between them. Aphria won five of the 13 lots, with Aurora Cannabis and Demecan handed five and three lots respectively.

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is acquiring the German-based, Bionorica SE-founded C3 Cannabinoid Compound Company in an all-cash deal valued at €225.9 million (CDN $342.9 million) or roughly $250 million. The move is intended to expand Canopy Growth’s reach in Europe.

Germany is awarding contracts to domestic cannabis growers in an attempt to develop its medical industry and become less reliant on imports.

BfArM – the Federal Institute for Drugs and Medical Devices of Germany – announced last Wednesday that it would purchase a total of 7,200 kilograms of cannabis over the next four years from German cultivation subsidiaries of Canadian companies Aurora Cannabis and Aphria.

A German cannabis wholesaler and distributor has announced that they have become the first European company to import medical cannabis products from Latin America for preliminary testing.

On Wednesday, Frankfurt-based Cansativa revealed that they would be importing a variety of cannabis flower and extract products from Uruguay and Colombia to be tested by independent German laboratories for heavy metals, pesticides, and other contaminants.

In 2013, Uruguay became the first country in the world to completely legalize marijuana, though sales did not begin until July of 2017.